Novel FC trials for the HVLT-R and BVMT-R may provide adjunctive indicators of noncredible performance. However, RD indices remain more sensitive overall. Though FC trials show promise, RD indices better classified invalid performance, and further research is needed before FC measures can be implemented widely.
Gradwohl et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: